vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 45.45 percent increase over losses of $(0.11) per share from the same period last year. The company reported $9.00 thousand in sales this quarter. This is the same as the same period last year.
Brown-Forman Records Revenue Beat, In-Line EPS In Q4
Brown-Forman Corp (NYSE:BF, BF-B)) reported Q4 FY23 sales growth of 5% Y/Y (+4% Y/Y on an organic basis) to $1.05 billion,…
